[Selective COX-2 inhibition improves endothelial function in coronary artery disease].
Schultz
Olaf
O
Universitätsklinikum Charité, Medizinische Universitätsklinik mit Schwerpunkt Rheumatologie, Schumannstrasse 20/21, 10117 Berlin, Germany. olaf.schultz@web.de
Buttgereit
Frank
F
D000368:Aged; D001158:Arteries / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology; D000068579:Celecoxib; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology*; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology; D051546:Cyclooxygenase 2; D004730:Endothelium, Vascular / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology*; D045462:Endothelium-Dependent Relaxing Factors / Q000008:administration & dosage; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D008565:Membrane Proteins; D008875:Middle Aged; D005996:Nitroglycerin / Q000008:administration & dosage; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D011720:Pyrazoles; D020127:Recovery of Function / Q000187:drug effects; D013449:Sulfonamides / Q000008:administration & dosage*; D016896:Treatment Outcome; D014463:Ultrasonography
D045462:Endothelium-Dependent Relaxing Factors; D007527:Isoenzymes; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D005996:Nitroglycerin; D000068579:Celecoxib